文献速递前列腺增生与排尿功能障碍泌尿系感染男科与性医学

钠-葡萄糖协同转运蛋白2抑制剂与泌尿系统疾病的关联:多州卫生系统分析对下尿路症状的启示

Associations Between Sodium-Glucose Co-transporter 2 Inhibitors and Urologic Diseases: Implications for Lower Urinary Tract Symptoms From a Multi-State Health System Analysis.
PubMed 文献 · Urology · 2024-06-20

基于多州卫生系统2014至2022年记录,分析163827例糖尿病患者,发现使用SGLT-2i与男性HbA1c≥7%者早期泌尿科转诊、龟头炎/包皮龟头炎、膀胱过度活动症、尿频、尿急及需LUTS药物频率较高相关,女性HbA1c≥7%者尿失禁率较高;多变量分析显示SGLT-2i使用可预测男性早期泌尿科转诊、龟头炎/包皮龟头炎、尿急、尿频、膀胱过度活动症及需LUTS药物。

要点

  • SGLT-2i使用与男性HbA1c≥7%者早期泌尿科转诊及多种下尿路症状诊断频率较高相关。
  • 女性HbA1c≥7%使用SGLT-2i者尿失禁率较高。
  • 多变量分析显示SGLT-2i使用可预测男性早期泌尿科转诊及LUTS相关诊断。

核心结论

  • SGLT-2i与其他糖尿病药物相比,可能导致更差的泌尿系统结局并增加泌尿科医疗利用。
  • 未来研究有必要识别哪些患者发生不良泌尿系统结局的风险最高。

研究设计与样本

  • 回顾多州卫生系统2014年至2022年记录,识别糖尿病药物处方后2年内转诊门诊泌尿科评估的患者。
  • 按处方SGLT-2i或其他糖尿病药物对患者进行分层,并比较1年内泌尿科就诊频率、泌尿系统诊断及治疗下尿路症状(LUTS)的处方。
  • 按治疗后是否达到HbA1c目标(≥7%或<7%)及性别对患者进行分层。
  • 进行多变量逻辑回归以确定SGLT-2i使用是否独立预测感兴趣结局。
  • 共163827例患者符合纳入标准。

主要发现

  • 在HbA1c≥7%的男性中,SGLT-2i使用与早期泌尿科转诊、龟头炎/包皮龟头炎、膀胱过度活动症、尿频、尿急及需LUTS药物频率较高相关。
  • 在HbA1c≥7%的女性中,SGLT-2i使用与尿失禁率较高相关。
  • 在HbA1c<7%者中,男性SGLT-2i队列仅龟头炎/包皮龟头炎较高,女性SGLT-2i队列仅尿失禁较高。
  • 多变量分析发现SGLT-2i使用可预测男性早期泌尿科转诊、龟头炎/包皮龟头炎、尿急、尿频、膀胱过度活动症及需LUTS药物。
  • 女性多变量分析显示类似结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the frequency of new urologic visits and urologic diagnoses in patients prescribed sodium-glucose co-transporter-2 inhibitors (SGLT-2is). MATERIAL AND METHODS: Records from a multi-state health system between 2014 and 2022 were reviewed to identify patients referred for outpatient urology evaluation within 2 years of diabetes medication prescription. Patients were stratified by the prescription of SGLT-2is or another diabetes medication. Frequency of urology visits within 1-year, urologic diagnoses, and prescriptions to treat lower urinary tract symptoms (LUTS) were compared. Patients were stratified by whether they had achieved HbA1c goal (≥7% or <7%) following treatment as well as by sex. Multivariable logistic regression was performed to determine if SGLT-2 use independently predicted outcomes of interest. RESULTS: 163,827 patients met inclusion criteria. Use of SGLT-2is was associated with a higher frequency of early urologic referral, balanitis/balanoposthitis, overactive bladder, urinary frequency, urgency, and need for LUTS medications in males with HbA1c ≥7%. Females on SGLT-2is with HbA1c ≥7% also had higher rates of urinary incontinence. In those with HbA1c <7%, only balanitis/balanoposthitis and urinary incontinence were higher in the SGLT-2i cohorts for males and females, respectively. Multivariable analysis found SGLT-2i use as predictive of early urology referral, balanitis/balanoposthitis, urinary urgency, frequency, overactive bladder, and need for LUTS medications in males. Multivariable analysis of females demonstrated similar results. CONCLUSION: SGLT-2is may lead to worse urologic outcomes and increased utilization of urologic care relative to other diabetic medications. Future studies are necessary to identify which patients are at highest risk of adverse urologic outcomes.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Roth BJ, Gill BC, Khooblall P, et al. Associations Between Sodium-Glucose Co-transporter 2 Inhibitors and Urologic Diseases: Implications for Lower Urinary Tract Symptoms From a Multi-State Health System Analysis. Urology. 2024. PMID: 38908564. doi:10.1016/j.urology.2024.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。